BHF Glasgow Cardiovascular Research Centre, University of Glasgow, 126 University Place, Glasgow G12 8TA, UK.
Eur J Heart Fail. 2010 Jul;12(7):698-705. doi: 10.1093/eurjhf/hfq070. Epub 2010 May 25.
To examine the relationship between baseline intermittent claudication and outcomes in patients enrolled in the Controlled Rosuvastatin Multinational Trial in Heart Failure trial (CORONA). Intermittent claudication is an independent predictor of worse outcome in coronary heart disease, but its prognostic importance in heart failure (HF) is unknown. Patients aged >or=60 years with NYHA class II-IV, low ejection fraction HF of ischaemic aetiology were enrolled in CORONA. Rosuvastatin did not reduce the primary outcome or all-cause mortality.
To determine whether intermittent claudication was an independent predictor of clinical outcomes, a three-step multivariable model was built: (i) demographic/clinical variables, (ii) biochemical measures added, (iii) high-sensitivity C-reactive protein and N-terminal pro B-type natriuretic-peptide added. Of the 5011 patients, 637 (12.7%) had intermittent claudication at baseline. Patients with intermittent claudication were more likely to be male (83 vs. 75%), be a current smoker (19 vs. 9%), and have diabetes mellitus (36 vs. 29%) relative to those without intermittent claudication. Over a median 33-month follow-up, 2168 patients died or were hospitalized for HF. Patients with intermittent claudication had an increased risk of death (any cause) (adjusted hazard ratio 1.36, 95% CI 1.19-1.56, P < 0.0001), death from worsening HF (1.35, 1.03-1.77, P = 0.028), sudden death (1.24, 1.00-1.54, P = 0.05), and risk of non-fatal or fatal myocardial infarction (time to first event 1.67, 1.24-2.27, P < 0.001). In the full multivariable model, intermittent claudication remained an independent predictor of most outcomes evaluated.
Intermittent claudication is a relatively common symptom in ischaemic HF and an independent predictor of worse outcome.
NCT00206310-http://clinicaltrials.gov/ct2/show/NCT00206310?term=corona&rank=2.
研究基线间歇性跛行与参与控制瑞舒伐他汀多国心力衰竭试验(CORONA)的患者结局之间的关系。间歇性跛行是冠心病不良预后的独立预测因素,但它在心力衰竭(HF)中的预后意义尚不清楚。CORONA 纳入了年龄> = 60 岁、NYHA 心功能 II-IV 级、射血分数低的缺血性病因心力衰竭患者。瑞舒伐他汀并未降低主要结局或全因死亡率。
为了确定间歇性跛行是否是临床结局的独立预测因素,建立了一个三步骤多变量模型:(i)人口统计学/临床变量,(ii)添加生化指标,(iii)添加高敏 C 反应蛋白和 N 末端 pro B 型利钠肽。在 5011 例患者中,637 例(12.7%)基线时有间歇性跛行。与无间歇性跛行的患者相比,有间歇性跛行的患者更可能为男性(83%比 75%)、当前吸烟者(19%比 9%)和患有糖尿病(36%比 29%)。中位随访 33 个月期间,2168 例患者死亡或因心力衰竭住院。有间歇性跛行的患者死亡(任何原因)的风险增加(校正后的危险比 1.36,95%CI 1.19-1.56,P < 0.0001)、因心力衰竭恶化而死亡(1.35,1.03-1.77,P = 0.028)、猝死(1.24,1.00-1.54,P = 0.05)和非致死性或致死性心肌梗死的风险(首次事件的时间 1.67,1.24-2.27,P < 0.001)。在全多变量模型中,间歇性跛行仍然是大多数评估结局的独立预测因素。
间歇性跛行是缺血性心力衰竭中一种相对常见的症状,是不良预后的独立预测因素。
NCT00206310-http://clinicaltrials.gov/ct2/show/NCT00206310?term=corona&rank=2.